Dicot Pharma has submitted clinical trial application for phase 2a trial
Uppsala, Sweden, July 8, 2024. Dicot Pharma announces today that a clinical trial application for a phase 2a trial with the drug candidate LIB-01, has been submitted. The trial is planned to start in the fourth quarter of 2024 as previously communicated. The trial is fully funded with the amount secured in advance in the announced rights issue that the company intends to carry out in August.Dicot is developing a new potency drug with the aim to treat erectile dysfunction better than existing drugs on the market. With good results from the company's recently completed phase 1 trial, a